Dasatinib

目录号：S1021 别名： BMS-354825

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

规格

价格

库存

购买数量

10mM/1mL In DMSO	RMB 1142.64	现货
25mg	RMB 1224.97	现货
100mg	RMB 3039.93	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献137篇：

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )
Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )
Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )
Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )
Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )
Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。

靶点

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型（除了T315I）的Ba/F3增殖时，Dasatinib效果比Imatinib高很多。与Imatinib相比，Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型（除了T315I）。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域，且抑制自磷酸化和底物磷酸化，这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时，效果比Imatinib高325倍多。^[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖，而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。^[2] Dasatinib 处理一系列甲状腺癌细胞，抑制Src信号, 降低生长速度,使细胞周期停滞，且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天，抑制50%细胞生长，然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP，SW1736 和 K1 细胞，导致G1期细胞提高9-22%，而S期细胞百分数则降低7-18%。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	M1TzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXy3NkBp	MoPkSG1UVw>?	M1jTSWlEPTB;MD6wNFAxPyEQvF2=	MXmxO\|k2PjB6MB?=
K562	M1zBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV7JcY93PzJiaB?=	NHjRVFVFVVOR	NEjUSlRKSzVyPUCuNFAyKM7:TR?=	NH2wNIcyPzl3NkC4NC=>
M07e	NVLBXWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXm3NkBp	NU\KcIpxTE2VTx?=	MUPJR\|UxRTBwMECxNkDPxE1?	NV\0e4tZOTd7NU[wPFA>
ALL3	MmjCR5l1d3SxeHnjJGF{e2G7	NEPLfFIxNjIQvF2=	MWq3NkBp	NHjaOWVFVVOR	NWnvV2s6UUN3ME2wMlAxODRizszN	NVHQe\|E{OTl6OEm1OFA>
CML	M4TtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYHhbpI3OjBibXnu	M37xfmROW09?	NYLpZVhOUUN3ME2wMlAxOSEQvF2=	Mn;VNVkzOTlyMU[=
BA/F3	M2\JUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUDzfphUPzJiaB?=	NGX5UodFVVOR	NEWzNHBKSzVyPU[uOVg6KM7:TR?=	MX:yN\|A5QDZ2NB?=
BA/F3	NFe0W3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGnWZ4M4OiCq	MVnEUXNQ	MYrJcoR2[2W\|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?=	MWKyN\|A5QDZ2NB?=
BA/F3	M1izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYS3NkBp	M{fiVGROW09?	NHWyOWhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2\|ryP	NF\Y[mgzOzB6OE[0OC=>
BA/F3	M2DrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV[3NkBp	MmTlSG1UVw>?	MmDrTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3OrbnegRoNzNUGkbDDUN\|E2USCvdYThcpQhf2m2aDDJR\|UxKG:oIEGuO\|E1\|ryP	NEDVbGUzOzB6OE[0OC=>
BA/F3	M4PHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYq5PFVzPzJiaB?=	M4\5fGROW09?	M1;RR2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6\|ryP	M1XHcFI{OzBzN{Cz
BA/F3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mnj2O\|IhcA>?	NFPPOFdFVVOR	M3PzZWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz\|ryP	NUnGdo5jOjN\|MEG3NFM>
BA/F3	M1fi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnjCO\|IhcA>?	Ml;BSG1UVw>?	NGLtZo9KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2Oc7:TR?=	MlPxNlM{ODF5MEO=
BA/F3	M4DxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYXKToUxPzJiaB?=	NWH2e5Y6TE2VTx?=	M2ftUWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFF{NULIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFjPxE1?	NFnye2wzOzNyMUewNy=>
BA/F3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3nzVlczKGh?	MoLYSG1UVw>?	Mm\STY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?	NEDDPZkzOzNyMUewNy=>
BA/F3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV[3NkBp	M2LjNGROW09?	M3rIfGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO	NF;Me4czOzNyMUewNy=>
BA/F3	NFXtUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVH1WVlOPzJiaB?=	M{H6WWROW09?	NX2wNJJkUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2=	MXOyN\|MxOTdyMx?=
BA/F3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVK3NkBp	MUDEUXNQ	MljHTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB\|LkdOwG0>	MonINlM{ODF5MEO=
BA/F3	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlW0O\|IhcA>?	M2\Ib2ROW09?	M{D3TWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?=	NVHVSXNsOjN\|MEG3NFM>
T cell	NHj5UnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17O[VczKGh?	MkjwSG1UVw>?	NYTSemFUUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1?	NGX0RWcyPzF3NEWxNi=>
WiDr	NFj0cIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXrQT2t3PzJiaB?=	MXvEUXNQ	M4[1SmlEPTB;MD6wOVIh\|ryP	NYjvdGlzOTV4MUW1NVI>
PC3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkXwO\|IhcA>?	NX[1Z3B3TE2VTx?=	NWTwUHhoUUN3ME2wMlAxQTRizszN	Mo\YNVU3OTV3MUK=
MDA-MB-231	M2jDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYjGTlZZPzJiaB?=	NEPITWxFVVOR	MnXMTWM2OD1yLkCxNkDPxE1?	NEXTOo4yPTZzNUWxNi=>
Hs578T	MkT4R5l1d3SxeHnjJGF{e2G7		NEDF[Jg4OiCq	M3L3O2ROW09?	Mn3BS2k2OD1yLkCzJO69VQ>?	M3rrSlI1ODF3M{K3
HMEC	NXvZVXlyS3m2b4TvfIlkKEG\|c3H5		MnvWO\|IhcA>?	Ml\kSG1UVw>?	MYrHTVUxRTFwODFOwG0>	MUmyOFAyPTN{Nx?=
DU145	MlTuR5l1d3SxeHnjJGF{e2G7		M4D1ZlczKGh?	NYDkPItqTE2VTx?=	Mm\GS2k2OD1yLkG2JO69VQ>?	M2HlPFI1ODF3M{K3
U251	MnntR5l1d3SxeHnjJGF{e2G7		M2qwT\|czKGh?	Mnz3SG1UVw>?	NGPVWlhIUTVyPUKuPFEh\|ryP	MnvZNlQxOTV\|Mke=
NCI60	Mnz3R5l1d3SxeHnjJGF{e2G7		Mn\tO\|IhcA>?	NXPhbVJHTE2VTx?=	NHS4W3hIUTVyPUWuO{DPxE1?	NH7ibmQzPDBzNUOyOy=>
MALME-3M	NGPaTllEgXSxdH;4bYMhSXO\|YYm=		M1PZUlczKGh?	NWG2VpZ{TE2VTx?=	M3L0cGdKPTB;Nj62NUDPxE1?	MmjhNlQxOTV\|Mke=
KM12	MV3DfZRwfG:6aXOgRZN{[Xl?		NFHn[Ig4OiCq	M1z2R2ROW09?	MUfHTVUxRTdwNESg{txO	M{PZZlI1ODF3M{K3
SW620	NXPoUW1{S3m2b4TvfIlkKEG\|c3H5		NVryV5M2PzJiaB?=	NWjrVXRnTE2VTx?=	Mny2S2k2OD16LkSzJO69VQ>?	M1:xe\|I1ODF3M{K3
RXF 393NL	NFfYbolEgXSxdH;4bYMhSXO\|YYm=		NYDDXGtTPCCmYYnz	MonXSG1UVw>?	M13nXGlEPTB;MD6wNlE4KM7:TR?=	M2TEPFI{OjV\|MEe0
LXFA 983L	MXLDfZRwfG:6aXOgRZN{[Xl?		NYfueWZ[PCCmYYnz	MVnEUXNQ	M4SzbmlEPTB;MD6wOVY2KM7:TR?=	NX3oUG1lOjN{NUOwO\|Q>
PRXF DU145	MmT3R5l1d3SxeHnjJGF{e2G7		MlfKOEBl[Xm\|	MWrEUXNQ	NUDG[WZmUUN3ME2wMlA3OjNizszN	MWSyN\|I2OzB5NB?=
PAXF 1657L	NHXKVYNEgXSxdH;4bYMhSXO\|YYm=		MkjyOEBl[Xm\|	MlPKSG1UVw>?	NXj1dm0yUUN3ME2wMlEzOSEQvF2=	NV\SRoRjOjN{NUOwO\|Q>
CXF 1103L	MXfDfZRwfG:6aXOgRZN{[Xl?		MnzDOEBl[Xm\|	NVTId5AxTE2VTx?=	M4jMZWlEPTB;ND6zOkDPxE1?	MkS0NlMzPTNyN{S=
GXF251L	M3vjcGN6fG:2b4jpZ{BCe3OjeR?=		NGDsWXg1KGSjeYO=	MUHEUXNQ	NX7BcWQxUUN3ME2yMlI2KM7:TR?=	NWTEe4xWOjN{NUOwO\|Q>
NCI-H23	MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{n5WlczKGh?	NYHmS3FjTE2VTx?=	M1LDcmlEPTB;Mj6yO{DPxE1?	MoPsNlM2OjFyMkC=
HCT116	NFu4[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUSy[IhqPzJiaB?=	NGfBS4JFVVOR	MY\JR\|UxRTJwMzFOwG0>	MmHONlM2OjFyMkC=
MCF7	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXjJNoRLPzJiaB?=	NEHaVJhFVVOR	M2\y[mlEPTB;Mj61O{DPxE1?	NED2UFAzOzV{MUCyNC=>
NCI-H460	M{DTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIrMZok4OiCq	M1vOdGROW09?	NXnzT2JZUUN3ME24Mlk6KM7:TR?=	MWGyN\|UzOTB{MB?=
DLD1	M1PUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVnHXmtCPzJiaB?=	NGm5PZdFVVOR	MUPJR\|UxRTRwNjFOwG0>	NHrRNpUzOzV4N{m2NC=>
NCI-H661	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn3lO\|IhcA>?	M3TtZWROW09?	MYTJR\|UxRTdwODFOwG0>	NIPXSFUzOzV4N{m2NC=>
A549	M{f0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{fQRlczKGh?	MlLXSG1UVw>?	M4PQbWlEPTB;OD6yJO69VQ>?	MmPZNlM2Pjd7NkC=
U937	NFLQR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYq3NkBp	NWn4d5puTE2VTx?=	MVjJR\|UxRTF{LkKg{txO	NYL6O29tOjN3Nke5OlA>
HEK293	M2f1RWZ2dmO2aX;uJGF{e2G7	NXW2N5llOTEEoN88US=>		M1jrWGROW09?	M17ocGlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ\|zszN	MX2yNlc4ODZzMB?=
HUVEC	MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2G1S\|AvOTYEoN88US=>	NGfOWlY4OiCq	NVfueYw6TE2VTx?=	NWq3RoZMUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO\|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO	NXS4bHdpOjJ6NUO5PVM>
HUVEC	NFHTZ4tHfW6ldHnvckBCe3OjeR?=	NEPOO28yPcLizszN	MlXkO\|IhcA>?	NUjWc4tiTE2VTx?=	M2TLT2lv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC\|bX;veIghdXW\|Y3zlJINmdGy\|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO	MoCyNlI5PTN7OUO=
Plasmodium falciparum	M4fkbGZ2dmO2aX;uJGF{e2G7	MX:xNOKh\|ryP	MUOxOUBucW5?	NFSzU3NFVVOR	MmfYTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO	NHnweVIzPDV3MEOzNC=>
PC3	NEezOmpHfW6ldHnvckBCe3OjeR?=	MlTBNE4yKM7:TR?=	NIi5U3Q2KGh?	MUXEUXNQ	MWfJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1?	NVLWNHNvOTl2NkK5O\|U>
DU145	NIPXe4hHfW6ldHnvckBCe3OjeR?=	MXmwMlEh\|ryP	MYO1JIg>	M4DKPGROW09?	NVjSbohsUW6qaXLpeJMhcHWvYX6gSHUyPDViY3XscEBi\Ginc3nvckBifCBzMECgcm0>	MW[xPVQ3Ojl5NR?=
PC3	NXu2b4N7U2mwYYPlJGF{e2G7	MXmwMlEh\|ryP	NYD1RpZRPSCq	NH;qZYdFVVOR	M4ezdWlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=	MYixPVQ3Ojl5NR?=
DU145	MYjLbY5ie2ViQYPzZZk>	M{KwN\|AvOSEQvF2=	MkG0OUBp	MmToSG1UVw>?	M{D0WGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=>	MkjFNVk1PjJ7N{W=
PC3	M1LPU2tqdmG\|ZTDBd5NigQ>?	MYiwMlEh\|ryP	MonFOUBp	M{PCZmROW09?	NECyUXpKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O\|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1?	NVXpOG4yOTl2NkK5O\|U>
DU145	NFjqZoVMcW6jc3WgRZN{[Xl?	M33acVAvOSEQvF2=	NIXmdVE2KGh?	NIfjZmRFVVOR	NWrBU4p[UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2=	M3TKXlE6PDZ{OUe1
Huh7	M{f2TWFvfGm4aYLhcEBCe3OjeR?=	NFzFSpYzNjVizszN	NETuSXQ1KGSjeYO=	NWi3VmtxTE2VTx?=	M1TNR2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=	NHfyO5kyPzN4ME[3Oi=>
C6/36	M1HCT2FvfGm4aYLhcEBCe3OjeR?=	Mnj4Nk42KM7:TR?=	NXfHNFgxPCCmYYnz	M3O2SGROW09?	NWKxbm5DUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=	M4TxNVE4OzZyNke2
U937	MoHJSpVv[3Srb36gRZN{[Xl?	MYGxJO69VQ>?	MYOxJIg>	M1TEcWROW09?	NUjPfYVvWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N\|ch[2WubIO=	NGnFe2MyPzZ6NEC5PS=>
U937	M3njW2Z2dmO2aX;uJGF{e2G7	MWCxJO69VQ>?	M4HESVEhcA>?	MmCwSG1UVw>?	MkPhVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM>	MofCNVc3QDRyOUm=
murine mast cell	NXzqe\|ZGTnWwY4Tpc44hSXO\|YYm=	M3rHfFEh\|ryP	M{PQTlI1KGh?	NIXJRpVFVVOR	MnG5TY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy\|IHH0JFEhfU1?	M1e5ZlE4Pjh2MEm5
BV-173	NVzSV2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEiwVpJKSzVyPUCuNFAxODByMUC5JO69VQ>?	NWX2WJl{W0GQR1XS
K-562	NX3SbWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUK2RmxUUUN3ME2wMlAxODByMEK2OkDPxE1?	NWPj[Wx{W0GQR1XS
BL-70	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;PTWp{UUN3ME2wMlAxODByMEiyNkDPxE1?	M1GwenNCVkeHUh?=
EM-2	Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\nUWlEPTB;MD6wNFAxODFyODFOwG0>	M3e3eHNCVkeHUh?=
LAMA-84	NGXrcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTBwMECwNFA{OjFizszN	MkHqV2FPT0WU
MEG-01	M4jRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfCdnlmUUN3ME2wMlAxODByOUig{txO	NXXqXHp1W0GQR1XS
EoL-1-cell	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwMECwNFE{OSEQvF2=	NVj1T5NsW0GQR1XS
CTV-1	NWq2NVJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\LTWM2OD1yLkCwNFA1ODRizszN	M{\JW3NCVkeHUh?=
TE-15	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTBwMEC1PFkh\|ryP	MnrJV2FPT0WU
NOS-1	MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnpWVY3UUN3ME2wMlAxPjF\|IN88US=>	NGjXZ5ZUSU6JRWK=
D-336MG	MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7KTWM2OD1yLkCwOlMh\|ryP	MofIV2FPT0WU
LB1047-RCC	NHW3TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\1TWM2OD1yLkCwPVg6KM7:TR?=	MlTRV2FPT0WU
LB996-RCC	NXzQc3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPITWM2OD1yLkCwPVkyKM7:TR?=	NX7jSIxSW0GQR1XS
SW982	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nJXGlEPTB;MD6wNVEyPSEQvF2=	MofSV2FPT0WU
TK10	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{S5OGlEPTB;MD6wNVE4PCEQvF2=	MnvMV2FPT0WU
A704	M{TEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Hle2lEPTB;MD6wNVQ6OSEQvF2=	MWDTRW5ITVJ?
TE-8	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\rWJc1UUN3ME2wMlAyPTd4IN88US=>	MXjTRW5ITVJ?
DOHH-2	NHLxW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLVR5ZEUUN3ME2wMlAyPzF7IN88US=>	NU\TbW5iW0GQR1XS
HOP-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULLVGxiUUN3ME2wMlAyQDN2IN88US=>	NUnyR21MW0GQR1XS
TE-12	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2O2c2lEPTB;MD6wNVg3OSEQvF2=	NUizZYV2W0GQR1XS
KGN	NF:xcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLpTGlKSzVyPUCuNFE6PDJizszN	M{fiZXNCVkeHUh?=
NCI-H1648	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorXTWM2OD1yLkCyNFEyKM7:TR?=	NYm1XmZ3W0GQR1XS
OS-RC-2	MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMEKwN{DPxE1?	M{jkTHNCVkeHUh?=
GB-1	NXfEdHNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXq1OpNvUUN3ME2wMlAzOTV5IN88US=>	M3LFe3NCVkeHUh?=
RXF393	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTBwMEKzOVch\|ryP	MX\TRW5ITVJ?
LC-2-ad	NYC3dYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwMEK1PFYh\|ryP	NWDTUYlXW0GQR1XS
KS-1	M1;qOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jRVWlEPTB;MD6wNlc{KM7:TR?=	NFznTYpUSU6JRWK=
ETK-1	NWP2NZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTBwMEK4N\|Ih\|ryP	MkK2V2FPT0WU
SW954	M4rzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTBwMEK5Nlch\|ryP	NHjnTGpUSU6JRWK=
Becker	NXvldpA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjq[Vd2UUN3ME2wMlA{ODB\|IN88US=>	M1vpUnNCVkeHUh?=
MZ1-PC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvqZ\|dmUUN3ME2wMlA{OTF7IN88US=>	M2\wSXNCVkeHUh?=
ES6	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\Hdo1KSzVyPUCuNFMyQTNizszN	M3W0[3NCVkeHUh?=
KURAMOCHI	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFr4T2lKSzVyPUCuNFM1QDdizszN	Mne4V2FPT0WU
CGTH-W-1	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTBwMEO1OFgh\|ryP	MlniV2FPT0WU
VA-ES-BJ	NHzER5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTBwMEO5NFIh\|ryP	Mn7nV2FPT0WU
LXF-289	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHtTWM2OD1yLkCzPVU3KM7:TR?=	MnzPV2FPT0WU
MPP-89	M1O3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofKTWM2OD1yLkC0NFQ6KM7:TR?=	NWXNSVVLW0GQR1XS
SW872	NEi3b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;MR\|NKSzVyPUCuNFQyPjFizszN	M{PJW3NCVkeHUh?=
SNB75	NISyd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlT3TWM2OD1yLkC0OFM2KM7:TR?=	NV\EUFVZW0GQR1XS
PSN1	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{e4VmlEPTB;MD6wOFQ4PCEQvF2=	NUPiUIZ5W0GQR1XS
LB831-BLC	NVTZTotsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDOTWM2OD1yLkC0OlA6KM7:TR?=	MnHRV2FPT0WU
MFH-ino	M2jEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\3[4hKSzVyPUCuNFQ4OjRizszN	M{P2fXNCVkeHUh?=
TGBC24TKB	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTBwMES3OlEh\|ryP	MVHTRW5ITVJ?
A388	NVv6V5VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jH[mlEPTB;MD6wOVA6PSEQvF2=	M2\ORnNCVkeHUh?=
BB30-HNC	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTBwMEW0N\|ch\|ryP	M4D2dnNCVkeHUh?=
GI-ME-N	NIPEOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fVeWlEPTB;MD6wOlEyQCEQvF2=	M{\rRnNCVkeHUh?=
TGBC1TKB	NHzvRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{m3SGlEPTB;MD6wOlE3PCEQvF2=	MmjXV2FPT0WU
TE-10	NYj6fWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4SxXmlEPTB;MD6wOlM2PyEQvF2=	NH71W4ZUSU6JRWK=
A498	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTBwMEeyPFQh\|ryP	M1z6OXNCVkeHUh?=
TE-11	M1\3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3IbWJ6UUN3ME2wMlA4QDV6IN88US=>	NFTaO3NUSU6JRWK=
BB65-RCC	NIDyTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPnTWM2OD1yLkC4NlI4KM7:TR?=	NXzYSoE6W0GQR1XS
C2BBe1	MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITBT2RKSzVyPUCuNFg{ODhizszN	M3nIWXNCVkeHUh?=
NCI-H747	MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHNOIJPUUN3ME2wMlA5OzZ{IN88US=>	NHP2bJNUSU6JRWK=
IST-MES1	M3fOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGr4OHFKSzVyPUCuNFg2PTJizszN	NX\ydXFyW0GQR1XS
KALS-1	NXvseYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLZTWM2OD1yLkC5OFkh\|ryP	M4H1e3NCVkeHUh?=
GCIY	Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTBwMEm2OVYh\|ryP	MXHTRW5ITVJ?
RL95-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTBwMUCzPEDPxE1?	NHfQ[VZUSU6JRWK=
TE-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\TN2lEPTB;MD6xNFU1KM7:TR?=	NUPiVlZRW0GQR1XS
NCI-H1355	NHHCNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfWepNNUUN3ME2wMlEyODJ6IN88US=>	NFrVNYpUSU6JRWK=
SW962	NXPac4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2OwUGlEPTB;MD6xNVI6OiEQvF2=	NH\jNGFUSU6JRWK=
KLE	NFTFbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVSzdFhDUUN3ME2wMlEyOzF5IN88US=>	MV\TRW5ITVJ?
MC116	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTBwMUG0NUDPxE1?	NInhUoNUSU6JRWK=
NMC-G1	NIPEVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTBwMUG2NFYh\|ryP	NFTzcG5USU6JRWK=
KU812	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mki2TWM2OD1yLkGxPFg{KM7:TR?=	NFzBfWdUSU6JRWK=
COLO-829	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULGfWl6UUN3ME2wMlEzOjF\|IN88US=>	NXj5V5pLW0GQR1XS
NTERA-S-cl-D1	NIPwRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHoTWM2OD1yLkGyNlg{KM7:TR?=	MV;TRW5ITVJ?
IST-MEL1	NWi3e2dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWW4[pNpUUN3ME2wMlE{PDVizszN	MXTTRW5ITVJ?
MLMA	M4\GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGO1OlBKSzVyPUCuNVQxOzJizszN	MXTTRW5ITVJ?
LS-123	NUP1Z\|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXKdWtPUUN3ME2wMlE1ODZ2IN88US=>	NIL1V\|VUSU6JRWK=
LB2518-MEL	M{faOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\5bYhFUUN3ME2wMlE1OTZ{IN88US=>	NIDoeFFUSU6JRWK=
NB69	Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXvTWM2OD1yLkG0OFM3KM7:TR?=	M1e5VXNCVkeHUh?=
8-MG-BA	MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwMUW0OVgh\|ryP	MkPpV2FPT0WU
K5	MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3KfpRVUUN3ME2wMlE3PDh7IN88US=>	M2PTUHNCVkeHUh?=
KINGS-1	NYriT5BqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvVTWM2OD1yLkG2OlY3KM7:TR?=	M1Pm[XNCVkeHUh?=
SF268	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrPU5RTUUN3ME2wMlE4PDB2IN88US=>	MVzTRW5ITVJ?
PF-382	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f5TWlEPTB;MD6xO\|Y4QCEQvF2=	NXfyOXdCW0GQR1XS
SH-4	NH;FdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTBTWM2OD1yLkG4OFE{KM7:TR?=	NIDmcnpUSU6JRWK=
NALM-6	NFXoUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zNN2lEPTB;MD6xPVI6PSEQvF2=	MnW5V2FPT0WU
CP66-MEL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPzPZlKSzVyPUCuNVk2OzFizszN	NWK0OFBwW0GQR1XS
697	NUXR[FFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrXTWM2OD1yLkG5PVg4KM7:TR?=	NWflOGo{W0GQR1XS
CP67-MEL	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFm0PXhKSzVyPUCuNlA1QDhizszN	M2f4R3NCVkeHUh?=
DSH1	NInYXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTBwMkSwNFEh\|ryP	NWDmUVN7W0GQR1XS
HCE-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV33emZmUUN3ME2wMlI3PDN7IN88US=>	NELuSVhUSU6JRWK=
MZ2-MEL	M4\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIW4[G9KSzVyPUCuNlg2OzdizszN	M3S1V3NCVkeHUh?=
BL-41	NVfXS4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXpTWM2OD1yLkK5NVI{KM7:TR?=	M4DXS3NCVkeHUh?=
HUTU-80	M{nHW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjr[m1KSzVyPUCuN\|E1OiEQvF2=	NVHNNpV4W0GQR1XS
LOXIMVI	M3fKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPvdY5MUUN3ME2wMlMyPTB\|IN88US=>	MULTRW5ITVJ?
no-10	NGrXWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkexTWM2OD1yLkOxPVMyKM7:TR?=	NY\UeFJoW0GQR1XS
KARPAS-422	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTBwM{O5PVch\|ryP	MUDTRW5ITVJ?
SW684	NX\lPIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfQbHZkUUN3ME2wMlM1QThizszN	M3:2ZnNCVkeHUh?=
SF126	NV\5[HFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LncmlEPTB;MD6zOVQyKM7:TR?=	MmLaV2FPT0WU
D-263MG	M{e4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLuTWM2OD1yLkO2NlI1KM7:TR?=	NUfhT3FkW0GQR1XS
OVCAR-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nQNmlEPTB;MD6zO\|Q{OyEQvF2=	MoT3V2FPT0WU
BB49-HNC	NWOzbJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPsVmtbUUN3ME2wMlM5PTl7IN88US=>	MWXTRW5ITVJ?
ONS-76	M4fjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHYTWM2OD1yLkSyPVUyKM7:TR?=	NYLXcIFjW0GQR1XS
MZ7-mel	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXUV3RuUUN3ME2wMlQ4QTFzIN88US=>	MYrTRW5ITVJ?
RCC10RGB	Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{O5TmlEPTB;MD60PVEyKM7:TR?=	MXzTRW5ITVJ?
BOKU	MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLJVVdKSzVyPUCuOFkyOzNizszN	NYjzO5NyW0GQR1XS
no-11	NGK3ZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrXTWM2OD1yLkWwNlI5KM7:TR?=	M1PTfnNCVkeHUh?=
IST-SL2	NWP1WIltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTETWM2OD1yLkWwN\|AzKM7:TR?=	M1GxXXNCVkeHUh?=
RKO	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkX5TWM2OD1yLkWyPVY3KM7:TR?=	NWnGToJnW0GQR1XS
HT-144	NF3VcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjkNZhKSzVyPUCuOVM3ODlizszN	Mki0V2FPT0WU
NCI-H446	NX3OfGJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rEUGlEPTB;MD62Nlc3KM7:TR?=	NEnNVWJUSU6JRWK=
QIMR-WIL	NUnRdplFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3WweGlEPTB;MD63NFYzQSEQvF2=	NWjtfVJGW0GQR1XS
MHH-PREB-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37PUGlEPTB;MD63OFQ3QSEQvF2=	M4\KSnNCVkeHUh?=
EW-16	NHrzdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwN{[xO\|gh\|ryP	Mnf0V2FPT0WU
EW-24	M{O2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\PZpJKSzVyPUCuO\|gyPjVizszN	NGjQUYRUSU6JRWK=
LB373-MEL-D	NYXEWZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\aTGtKSzVyPUCuPFI2ODhizszN	MmLGV2FPT0WU
TE-9	NGrmdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLMTWM2OD1yLki3OVMzKM7:TR?=	NUnTPYJpW0GQR1XS
A3-KAW	M2H6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTNTXNVUUN3ME2wMlk5PDV{IN88US=>	NWPvOpZvW0GQR1XS
A101D	Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3NTWM2OD1zLkCzNFQ{KM7:TR?=	Ml\IV2FPT0WU
OCUB-M	M4fORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELCS3FKSzVyPUGuNFQ1OTJizszN	MlTIV2FPT0WU
ES4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLyNW9KSzVyPUGuNFUyPDVizszN	NHTDUXRUSU6JRWK=
TE-6	NHXJV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jH[GlEPTB;MT6yNVIzPiEQvF2=	MUHTRW5ITVJ?
D-502MG	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFwMkOzO\|Yh\|ryP	NWL6WpZEW0GQR1XS
KNS-42	NXTvdlNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\iV4hKSzVyPUGuNlQ1OTJizszN	NH\x[nhUSU6JRWK=
SNU-C2B	MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTFwM{C1PFkh\|ryP	MorBV2FPT0WU
NCI-H1838	M1PPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TCTWlEPTB;MT6zNFc{OyEQvF2=	M2LFPXNCVkeHUh?=
NKM-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XWVmlEPTB;MT6zNFg2QSEQvF2=	MVHTRW5ITVJ?
GI-1	NYi4fGVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwM{[yNkDPxE1?	MkTiV2FPT0WU
NB5	NHvWWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7pZ4VKSzVyPUGuN\|k5OjdizszN	NGXGc4tUSU6JRWK=
CAS-1	NXric2pFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XJS2lEPTB;MT60NFk6OiEQvF2=	NEDPdWhUSU6JRWK=
HCE-T	NInqbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLve\|JXUUN3ME2xMlU3PzF2IN88US=>	MkLFV2FPT0WU
SBC-1	NVz1UoRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Ti[mlEPTB;MT61O\|k5PCEQvF2=	M{[0enNCVkeHUh?=
JiyoyeP-2003	NHOyNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHSN\|NuUUN3ME2xMlc{PDZ4IN88US=>	MYfTRW5ITVJ?
TE-5	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjuWIxqUUN3ME2xMlc6OTN7IN88US=>	NV7xOFBzW0GQR1XS
CAN	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFwOEKyOVIh\|ryP	NYS1dW5ZW0GQR1XS
SK-UT-1	NFvi[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTFOYx4UUN3ME2yMlE3Pjl\|IN88US=>	M2P1UHNCVkeHUh?=
JVM-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHO1eFRKSzVyPUKuN\|YzQDRizszN	NGK4fXdUSU6JRWK=
LB771-HNC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnpV\|l2UUN3ME2yMlU4PTVzIN88US=>	NWL0OYVuW0GQR1XS
NCCIT	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPMXItmUUN3ME2yMlg3PjF4IN88US=>	Mnq5V2FPT0WU
NCI-H2126	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3DPI51UUN3ME2yMlg4PTV{IN88US=>	Mk\TV2FPT0WU
Calu-6	M{TrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3X3U2lEPTB;Mz6wOVc1OSEQvF2=	MU\TRW5ITVJ?
SK-LMS-1	NEnZRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkWyTWM2OD1\|LkGxPFg3KM7:TR?=	MYfTRW5ITVJ?
ARH-77	M{HpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHwTWM2OD1\|LkS2PVE2KM7:TR?=	MX\TRW5ITVJ?
NB17	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DqcGlEPTB;Mz62N\|g1PyEQvF2=	NVLNWXdWW0GQR1XS
A253	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\JbmpWUUN3ME2zMlc{OjR4IN88US=>	Moj5V2FPT0WU
OPM-2	M3jNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPOTphHUUN3ME20MlI4Pjh3IN88US=>	M4XCR3NCVkeHUh?=
MV-4-11	M3ToSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYj5O5g5UUN3ME20MlM3PDV2IN88US=>	MULTRW5ITVJ?
SR	M1LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;selZKSzVyPUSuOFk6PTRizszN	M1XmSXNCVkeHUh?=
KG-1	NWi1NpFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LiVmlEPTB;ND62NFg1PSEQvF2=	MV;TRW5ITVJ?
OCI-AML2	NI\NfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLETWM2OD13Lki2NVU1KM7:TR?=	M3PBb3NCVkeHUh?=
D-247MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTZwMUK1NVkh\|ryP	NY\ufolGW0GQR1XS
DJM-1	M2jqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3Tx[2lEPTB;Nj60PFU2QCEQvF2=	NF;KS5JUSU6JRWK=
RPMI-6666	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4q3SmlEPTB;Nz6yO\|A3PyEQvF2=	NU\XcoF3W0GQR1XS
KARPAS-45	NVTmb\|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnnbYZTUUN3ME23MlUyPjdzIN88US=>	NIPhNoRUSU6JRWK=
LP-1	NHj2VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFL6TXRKSzVyPUeuOVQ4QDJizszN	M3jwfnNCVkeHUh?=
RS4-11	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jofGlEPTB;Nz62OVc5PyEQvF2=	NG[0TGlUSU6JRWK=
DU-4475	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRThwMkG2OVIh\|ryP	M3nVOHNCVkeHUh?=
MONO-MAC-6	NHzHWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkizTWM2OD16LkK3NFY3KM7:TR?=	MoD3V2FPT0WU
NCI-SNU-16	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFyyPZRKSzVyPUiuOVYyOjhizszN	MXnTRW5ITVJ?
SJSA-1	M4j1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlq3TWM2OD16LkeyPFA2KM7:TR?=	NWLCfYtFW0GQR1XS
MMAC-SF	NFfyZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRThwN{mzNFch\|ryP	MVPTRW5ITVJ?
SK-NEP-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\SXG9KSzVyPUiuPFkyPTVizszN	NVzyWG1WW0GQR1XS
J-RT3-T3-5	NGPvXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rHdWlEPTB;OD65OlUzQSEQvF2=	NGHrT2RUSU6JRWK=
SKM-1	NYfV[oZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLOV3hDUUN3ME25MlAyPzN2IN88US=>	MV;TRW5ITVJ?
LB2241-RCC	NIrVSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVj3R4RsUUN3ME25MlAzODF{IN88US=>	Ml;iV2FPT0WU
SIG-M5	NXO4OmZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGT3W4VKSzVyPUmuNFI1QTNizszN	MnPLV2FPT0WU
EVSA-T	MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPsOot6UUN3ME25MlI4Pzl\|IN88US=>	NUjjR3hlW0GQR1XS
GT3TKB	Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rmRWlEPTB;OT6zOVU1PiEQvF2=	NWL3fpRGW0GQR1XS
NB6	M2DpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrqZ3ZKSzVyPUmuPVIzPTlizszN	M3fIN3NCVkeHUh?=
EHEB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Ho[WlEPTB;MUCuNFY2PiEQvF2=	MXfTRW5ITVJ?
HEL	M2PaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFyLkS3O\|Yh\|ryP	MVjTRW5ITVJ?
ALL-PO	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTFyLke5N\|gh\|ryP	NHjZPGlUSU6JRWK=
TGW	NHLsdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFzLkK4Nlgh\|ryP	NGrBWpZUSU6JRWK=
BC-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPNTWM2OD1zMj6xNVM5KM7:TR?=	NH7lbZRUSU6JRWK=
IA-LM	MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTF{LkS0OFUh\|ryP	NXTl[IxUW0GQR1XS
UACC-257	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrjSZZKSzVyPUGyMlkyQThizszN	NIn3NJJUSU6JRWK=
KP-N-YS	NU\1cox2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTF{LkmyPFMh\|ryP	NYLFNHNWW0GQR1XS
Raji	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLrTWM2OD1zMz63OFk4KM7:TR?=	M{\BSHNCVkeHUh?=
SF539	NIruVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTF\|Lki1OVch\|ryP	NVvZNWF7W0GQR1XS
DMS-153	M1\YTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzBTWM2OD1zND6wNFI5KM7:TR?=	MY\TRW5ITVJ?
L-540	NGT4W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELRV25KSzVyPUG1MlA3PzJizszN	MWHTRW5ITVJ?
MN-60	M13Uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3pWoVHUUN3ME2xOU4yQTd7IN88US=>	MV3TRW5ITVJ?
RPMI-8866	NHjRO\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:2ZVJKSzVyPUG3MlQ1PTRizszN	NGPwcYJUSU6JRWK=
NCI-H510A	NX\wToNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXLenBpUUN3ME2xPU4{QTd\|IN88US=>	NXrQS\|NIW0GQR1XS
NB13	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDSTWM2OD1zOT60PFc4KM7:TR?=	NWrhepZ[W0GQR1XS
HAL-01	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfXTWM2OD1zOT63OVQ{KM7:TR?=	NWHiO5hUW0GQR1XS
NCI-H720	M3mxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrUT4w{UUN3ME2yNE4zPzN\|IN88US=>	MXXTRW5ITVJ?
REH	MmDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJyLk[zOVch\|ryP	NITUV2dUSU6JRWK=
KNS-81-FD	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvMTWM2OD1{Mz6xOFYh\|ryP	MoXBV2FPT0WU
HC-1	NUHwN3p5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILXclhKSzVyPUK0MlU2PTFizszN	MULTRW5ITVJ?
NCI-H2141	NES2dHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPDTWM2OD1{ND63O\|U1KM7:TR?=	NGTib2NUSU6JRWK=
MOLT-4	NUjw[otOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D1RWlEPTB;Mk[uOlc2OyEQvF2=	MYDTRW5ITVJ?
OMC-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEX6eI5KSzVyPUK3MlE1OjJizszN	MmCyV2FPT0WU
LC-1F	NFnaTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\x[XZIUUN3ME2yO{4{OjR3IN88US=>	M3PSNXNCVkeHUh?=
NCI-H1304	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJ6LkG2Nlgh\|ryP	NYLvN2dIW0GQR1XS
BC-1	M2TZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;NTWM2OD1{OD62OVEh\|ryP	NWXIT25CW0GQR1XS
NCI-H64	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTJ7Lk[yOVMh\|ryP	M3[wRnNCVkeHUh?=
MOLT-16	M4PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLH[4c4UUN3ME2yPU43Ojl{IN88US=>	NH\mfldUSU6JRWK=
U-87-MG	NWmwdlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\PTmlEPTB;M{CuO\|Y3KM7:TR?=	NIDFRmNUSU6JRWK=
GAK	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorYTWM2OD1\|MT6yOlg3KM7:TR?=	NInXXo5USU6JRWK=
ES8	NF\UVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjSUHJDUUN3ME2zNk4yOjV{IN88US=>	NVSxRpRiW0GQR1XS
HCC1599	NHP4c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTN{LkOzNlUh\|ryP	NH[2SppUSU6JRWK=
EB-3	Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDGSFhvUUN3ME2zOE4{OTF5IN88US=>	M3nUTnNCVkeHUh?=
HCC1187	NVTGRZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTN3LkiwOVIh\|ryP	M4\lOHNCVkeHUh?=
SK-PN-DW	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXuOXQ5UUN3ME2zOk4yQTR\|IN88US=>	NEmyPIFUSU6JRWK=
JVM-3	NEXrV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTN5LkKzN\|gh\|ryP	M1PWVXNCVkeHUh?=
HCC2157	NH;kVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HkdmlEPTB;M{euPVk1PiEQvF2=	M3z1fXNCVkeHUh?=
A4-Fuk	NEf5flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTN6LkGwNFkh\|ryP	MYjTRW5ITVJ?
COR-L279	NGHpdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfz[YpLUUN3ME20NE4zQDVzIN88US=>	M2jnfnNCVkeHUh?=
DEL	NF\kNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTRzLkmwPFYh\|ryP	NGH6S2JUSU6JRWK=
NCI-H1395	Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXhTWM2OD12Mj6wNVY{KM7:TR?=	M2LkR3NCVkeHUh?=
MHH-NB-11	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PY[GlEPTB;NEOuNFgyQCEQvF2=	M4\W[HNCVkeHUh?=
NCI-H2107	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFSyTpBKSzVyPUSzMlQ5PDZizszN	NUHSPYM3W0GQR1XS
NEC8	NIT4bnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkP1TWM2OD12ND6zN\|Yh\|ryP	MUTTRW5ITVJ?
COLO-684	NYX1SpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXrTWM2OD12Nj6yNlU5KM7:TR?=	NVHnPGJuW0GQR1XS
LS-411N	NHvCbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fGNmlEPTB;NEiuOFc1QCEQvF2=	M1mzPXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

体内研究

Dasatinib 作用于LMP2A/MYC 双转基因小鼠，可逆转脾肿大。Dasatinib 作用于TgE小鼠抑制表达LMP2A 的骨髓B 细胞形成的菌落，且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠，与对照组相比，脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠，抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠，可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤，抑制Lyn磷酸化。^[2]

激酶实验：^[1]	+ 展开激酶自磷酸化分析: 使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白，ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30^oC下温育1小时后,加入1 mM 钒酸钠，激活LAR磷酸酶。进行免疫印迹分析，比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶，使用磷酸化的特点抗体4G10来确认酪氨酸残基完全去磷酸化(>95%)，使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验： ^[1]	+ 展开 Cell lines: Ba/F3细胞系 Concentrations: 0 nM-32 nM Incubation Time: 72小时 Method: Ba/F3 细胞系重复培养三份，然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。 (Only for Reference)
动物实验：^[2]	+ 展开 Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC) Formulation: DMSO Dosages: 30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

+ 展开

溶解度 (25°C)

体外	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dasatinib SDF

分子量	488.01
化学式	C₂₂H₂₆ClN₇O₂S
CAS号	302962-49-8
储存条件	3 years -20°C powder
储存条件	2 years -80°C in solvent
别名	BMS-354825

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Not yet recruiting	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	December 2019	Phase 1\|Phase 2
NCT04115059	Not yet recruiting	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 2019	Phase 1
NCT03318770	Not yet recruiting	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2
NCT03193281	Recruiting	Chronic Myeloid Leukemia	University of Auckland New Zealand\|Leukaemia & Blood Cancer New Zealand	July 17 2017	Phase 2
NCT03041701	Recruiting	Rhabdomyosarcoma\|Rhabdomyosarcoma- Alveolar\|Rhabdomyosarcoma-Embryonal	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	July 7 2017	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
回答：
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
问题 2：
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
回答：
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

泛Src抑制剂

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA批准的Src抑制剂

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
最新的Src抑制剂

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
经典的Src抑制剂

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

研究领域

产品类型

Dasatinib

客户使用Selleck该产品发表文献137篇：

产品安全说明书

Src抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dasatinib SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on )

技术支持

常见问题及建议解决方法

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品